{"id":"https://openalex.org/W7223456142","doi":"https://doi.org/10.1200/jco-26-02166","title":"Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis","display_name":"Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis","publication_year":2026,"publication_date":"2026-10-24","ids":{"openalex":"https://openalex.org/W7223456142","doi":"https://doi.org/10.1200/jco-26-02166","pmid":"https://pubmed.ncbi.nlm.nih.gov/42921711"},"language":"en","primary_location":{"id":"doi:10.1200/jco-26-02166","doi":"https://doi.org/10.1200/jco-26-02166","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco-26-02166","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-26-02166","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-26-02166","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064903587","display_name":"Neil D. Gross","orcid":"https://orcid.org/0000-0002-9427-0743","observed_orcids":["https://orcid.org/0000-0002-9427-0743"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil D. Gross","raw_affiliation_strings":["University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0002-9427-0743","affiliations":[{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087891557","display_name":"David Michael Miller","orcid":"https://orcid.org/0000-0001-9736-9119","observed_orcids":["https://orcid.org/0000-0001-9736-9119"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I48633490","display_name":"Mass General Brigham","ror":"https://ror.org/04py2rh25","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Miller","raw_affiliation_strings":["Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I48633490"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058902095","display_name":"Nikhil I. Khushalani","orcid":"https://orcid.org/0000-0002-3636-4143","observed_orcids":["https://orcid.org/0000-0002-3636-4143"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil I. Khushalani","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":"https://orcid.org/0000-0002-3636-4143","affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015300924","display_name":"Vasu Divi","orcid":"https://orcid.org/0000-0002-6219-6294","observed_orcids":["https://orcid.org/0000-0002-6219-6294"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vasu Divi","raw_affiliation_strings":["Stanford University School of Medicine, Stanford, CA"],"raw_orcid":"https://orcid.org/0000-0002-6219-6294","affiliations":[{"raw_affiliation_string":"Stanford University School of Medicine, Stanford, CA","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043968037","display_name":"Emily Stamell Ruiz","orcid":"https://orcid.org/0000-0001-5824-2721","observed_orcids":["https://orcid.org/0000-0001-5824-2721"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily S. Ruiz","raw_affiliation_strings":["Brigham and Women's Hospital, Harvard Medical School, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-5824-2721","affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014494747","display_name":"Evan J. Lipson","orcid":"https://orcid.org/0000-0003-2976-0911","observed_orcids":["https://orcid.org/0000-0003-2976-0911"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evan J. Lipson","raw_affiliation_strings":["Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"],"raw_orcid":"https://orcid.org/0000-0003-2976-0911","affiliations":[{"raw_affiliation_string":"Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037516725","display_name":"Friedegund Elke Meier","orcid":"https://orcid.org/0000-0003-4340-9706","observed_orcids":["https://orcid.org/0000-0003-4340-9706"]},"institutions":[{"id":"https://openalex.org/I4210111460","display_name":"National Center for Tumor Diseases","ror":"https://ror.org/01txwsw02","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I1305996414","https://openalex.org/I17937529","https://openalex.org/I223822909","https://openalex.org/I2802164966","https://openalex.org/I4210111460"]},{"id":"https://openalex.org/I4387153526","display_name":"Nationales Centrum f\u00fcr Tumorerkrankungen Dresden","ror":"https://ror.org/01zy07c70","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I1305996414","https://openalex.org/I17937529","https://openalex.org/I2801798921","https://openalex.org/I4210162051","https://openalex.org/I4387153526","https://openalex.org/I78650965"]},{"id":"https://openalex.org/I78650965","display_name":"Technische Universit\u00e4t Dresden","ror":"https://ror.org/042aqky30","country_code":"DE","type":"education","lineage":["https://openalex.org/I78650965"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Friedegund Meier","raw_affiliation_strings":["Technische Universit\u00e4t Dresden and Skin Cancer Center at University Cancer Centre Dresden and National Center for Tumor Diseases, Dresden, Germany"],"raw_orcid":"https://orcid.org/0000-0003-4340-9706","affiliations":[{"raw_affiliation_string":"Technische Universit\u00e4t Dresden and Skin Cancer Center at University Cancer Centre Dresden and National Center for Tumor Diseases, Dresden, Germany","institution_ids":["https://openalex.org/I4210111460","https://openalex.org/I4387153526","https://openalex.org/I78650965"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113885801","display_name":"Yungpo Bernard Su","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153252","display_name":"Nebraska Cancer Specialists","ror":"https://ror.org/052z1v370","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153252"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yungpo Bernard Su","raw_affiliation_strings":["Nebraska Cancer Specialists, Omaha, NE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nebraska Cancer Specialists, Omaha, NE","institution_ids":["https://openalex.org/I4210153252"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053392688","display_name":"Paul Loren Swiecicki","orcid":"https://orcid.org/0000-0003-2286-3555","observed_orcids":["https://orcid.org/0000-0003-2286-3555"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul L. Swiecicki","raw_affiliation_strings":["University of Michigan, Ann Arbor, MI"],"raw_orcid":"https://orcid.org/0000-0003-2286-3555","affiliations":[{"raw_affiliation_string":"University of Michigan, Ann Arbor, MI","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083345758","display_name":"Jennifer Atlas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Atlas","raw_affiliation_strings":["Atrium Health/Advocate Health, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Atrium Health/Advocate Health, Charlotte, NC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009234841","display_name":"Jessica L. Geiger","orcid":"https://orcid.org/0000-0003-4990-007X","observed_orcids":["https://orcid.org/0000-0003-4990-007X"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica L. Geiger","raw_affiliation_strings":["Cleveland Clinic, Cleveland, OH"],"raw_orcid":"https://orcid.org/0000-0003-4990-007X","affiliations":[{"raw_affiliation_string":"Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044736874","display_name":"Axel Hauschild","orcid":"https://orcid.org/0000-0002-1212-9587","observed_orcids":["https://orcid.org/0000-0002-1212-9587"]},"institutions":[{"id":"https://openalex.org/I4210112713","display_name":"University Hospital Schleswig-Holstein","ror":"https://ror.org/01tvm6f46","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210112713"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Axel Hauschild","raw_affiliation_strings":["Schleswig-Holstein University Hospital, Kiel, Germany"],"raw_orcid":"https://orcid.org/0000-0002-1212-9587","affiliations":[{"raw_affiliation_string":"Schleswig-Holstein University Hospital, Kiel, Germany","institution_ids":["https://openalex.org/I4210112713"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023328967","display_name":"Jennifer Hsing Choe","orcid":"https://orcid.org/0000-0002-9279-0235","observed_orcids":["https://orcid.org/0000-0002-9279-0235"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Hsing Choe","raw_affiliation_strings":["Duke Cancer Institute, Durham, NC"],"raw_orcid":"https://orcid.org/0000-0002-9279-0235","affiliations":[{"raw_affiliation_string":"Duke Cancer Institute, Durham, NC","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051086683","display_name":"Brett G.M. Hughes","orcid":"https://orcid.org/0000-0002-1811-0537","observed_orcids":["https://orcid.org/0000-0002-1811-0537"]},"institutions":[{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]},{"id":"https://openalex.org/I2799393793","display_name":"Royal Brisbane and Women's Hospital","ror":"https://ror.org/05p52kj31","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I1302211766","https://openalex.org/I2799393793","https://openalex.org/I2801244131"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Brett G.M. Hughes","raw_affiliation_strings":["Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, QLD, Australia"],"raw_orcid":"https://orcid.org/0000-0002-1811-0537","affiliations":[{"raw_affiliation_string":"Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, QLD, Australia","institution_ids":["https://openalex.org/I165143802","https://openalex.org/I2799393793"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026878751","display_name":"Annette May Ling Lim","orcid":"https://orcid.org/0000-0002-0777-2279","observed_orcids":["https://orcid.org/0000-0002-0777-2279"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Annette M. Lim","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, VIC, Australia","University of Melbourne, Melbourne, VIC, Australia"],"raw_orcid":"https://orcid.org/0000-0002-0777-2279","affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia","institution_ids":["https://openalex.org/I2800555584"]},{"raw_affiliation_string":"University of Melbourne, Melbourne, VIC, Australia","institution_ids":["https://openalex.org/I165779595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007020035","display_name":"Renata Ferrarotto","orcid":"https://orcid.org/0000-0002-3561-215X","observed_orcids":["https://orcid.org/0000-0002-3561-215X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Renata Ferrarotto","raw_affiliation_strings":["University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0002-3561-215X","affiliations":[{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071132696","display_name":"Bei Wang","orcid":"https://orcid.org/0000-0002-1639-584X","observed_orcids":["https://orcid.org/0000-0002-1639-584X"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bei Wang","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":"https://orcid.org/0000-0002-1639-584X","affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5157553193","display_name":"Weiwei Tao","orcid":"https://orcid.org/0009-0003-2579-0037","observed_orcids":["https://orcid.org/0009-0003-2579-0037"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weiwei Tao","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020980411","display_name":"Laura Brennan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Brennan","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022850951","display_name":"Suk\u2010Young Yoo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Suk-Young Yoo","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024340047","display_name":"F.A. Seebach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank Seebach","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031475492","display_name":"Israel Lowy","orcid":"https://orcid.org/0000-0002-5421-2485","observed_orcids":["https://orcid.org/0000-0002-5421-2485"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Israel Lowy","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":"https://orcid.org/0000-0002-5421-2485","affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026335885","display_name":"Melissa Divya Mathias","orcid":"https://orcid.org/0000-0001-6026-601X","observed_orcids":["https://orcid.org/0000-0001-6026-601X"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Mathias","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104103467","display_name":"Hyunsil Han","orcid":"https://orcid.org/0009-0008-7822-2291","observed_orcids":["https://orcid.org/0009-0008-7822-2291"]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hyunsil Han","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":"https://orcid.org/0009-0008-7822-2291","affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072271778","display_name":"Matthew G. Fury","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I186523950","display_name":"Regeneron (United States)","ror":"https://ror.org/02f51rf24","country_code":"US","type":"company","lineage":["https://openalex.org/I186523950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew G. Fury","raw_affiliation_strings":["Regeneron Pharmaceuticals, Inc, Tarrytown, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regeneron Pharmaceuticals, Inc, Tarrytown, NY","institution_ids":["https://openalex.org/I186523950"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060469120","display_name":"Danny Rischin","orcid":"https://orcid.org/0000-0002-3368-0386","observed_orcids":["https://orcid.org/0000-0002-3368-0386"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Danny Rischin","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, VIC, Australia","University of Melbourne, Melbourne, VIC, Australia"],"raw_orcid":"https://orcid.org/0000-0002-3368-0386","affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia","institution_ids":["https://openalex.org/I2800555584"]},{"raw_affiliation_string":"University of Melbourne, Melbourne, VIC, Australia","institution_ids":["https://openalex.org/I165779595"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":23,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.8449235,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"JCO2602166","last_page":"JCO2602166"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cemiplimab","display_name":"cemiplimab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/neoadjuvant-immunotherapy","display_name":"neoadjuvant immunotherapy","score":0.9179999828338623},{"id":"https://openalex.org/keywords/cutaneous-squamous-cell-carcinoma","display_name":"cutaneous squamous cell carcinoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.796999990940094},{"id":"https://openalex.org/keywords/pathological-complete-response","display_name":"pathological complete response","score":0.8769999742507935},{"id":"https://openalex.org/keywords/event-free-survival","display_name":"event-free survival","score":0.9900000095367432},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9990000128746033},{"id":"https://openalex.org/keywords/recurrence","display_name":"recurrence","score":0.8399999737739563},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.5080000162124634}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8804000020027161},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.6276999711990356},{"id":"https://openalex.org/C3019992690","wikidata":"https://www.wikidata.org/wiki/Q92767510","display_name":"Basal cell","level":2,"score":0.5853999853134155},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49630001187324524},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.4927999973297119},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4650999903678894},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4643999934196472},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4388999938964844},{"id":"https://openalex.org/C2778292576","wikidata":"https://www.wikidata.org/wiki/Q6991934","display_name":"Neoadjuvant therapy","level":4,"score":0.43369999527931213},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.40149998664855957},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.38989999890327454},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.37139999866485596},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35740000009536743},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.3456999957561493},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3287000060081482},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.30640000104904175},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3059999942779541},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.301800012588501},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.26080000400543213},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.2565000057220459},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.2549000084400177},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.251800000667572}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco-26-02166","doi":"https://doi.org/10.1200/jco-26-02166","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco-26-02166","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-26-02166","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:42921711","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42921711","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1200/jco-26-02166","doi":"https://doi.org/10.1200/jco-26-02166","is_oa":true,"landing_page_url":"https://doi.org/10.1200/jco-26-02166","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-26-02166","source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320314128","display_name":"Les Laboratories Pierre Fabre","ror":"https://ror.org/04hdhz511"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320319840","display_name":"Coherus Biosciences","ror":"https://ror.org/00mjj2d85"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320328070","display_name":"Sun Pharma","ror":"https://ror.org/04vnqkx80"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332200","display_name":"EMD Serono","ror":"https://ror.org/027zrs220"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223456142.pdf","grobid_xml":"https://content.openalex.org/works/W7223456142.grobid-xml"},"referenced_works_count":11,"referenced_works":["https://openalex.org/W2148561698","https://openalex.org/W2810879984","https://openalex.org/W3038075739","https://openalex.org/W4295271013","https://openalex.org/W4322718735","https://openalex.org/W4385322327","https://openalex.org/W4387845173","https://openalex.org/W4407586349","https://openalex.org/W4412532628","https://openalex.org/W4414364424","https://openalex.org/W4414930823"],"related_works":["https://openalex.org/W4387811079","https://openalex.org/W4409144623","https://openalex.org/W4410560853","https://openalex.org/W4387845173","https://openalex.org/W4296008874","https://openalex.org/W4295271013","https://openalex.org/W4401800557","https://openalex.org/W4379281085","https://openalex.org/W4416088056","https://openalex.org/W4400765064"],"abstract_inverted_index":{"We":[0],"previously":[1],"reported":[2],"the":[3,30,39],"results":[4],"of":[5,14,68],"a":[6,65],"multicenter":[7],"phase":[8],"II":[9,20],"trial":[10],"(ClinicalTrials.gov":[11],"identifier:":[12],"NCT04154943)":[13],"neoadjuvant":[15,169],"cemiplimab":[16],"in":[17,28,105,110,117,125],"resectable":[18],"stage":[19],"to":[21],"IV":[22],"cutaneous":[23],"squamous":[24],"cell":[25],"carcinoma":[26],"(CSCC),":[27],"which":[29],"pathologic":[31,114,121],"complete":[32],"response":[33],"(pCR)":[34],"rate":[35],"was":[36,47,102,142],"51%.":[37],"At":[38],"19-month":[40],"follow-up,":[41],"estimated":[42,99,139],"12-month":[43],"event-free":[44],"survival":[45,62],"(EFS)":[46],"89%,":[48],"with":[49,107,112,119,131,168],"11":[50],"EFS":[51,59,73,89,101,157],"events.":[52,85],"In":[53],"this":[54],"study,":[55],"we":[56],"report":[57],"final":[58,77,153],"and":[60,123,158,163],"overall":[61],"(OS)":[63],"at":[64,76],"median":[66],"follow-up":[67],"54":[69],"months.":[70],"Overall,":[71],"16":[72],"events":[74,90,150],"occurred":[75],"analysis.":[78],"There":[79],"were":[80,91],"no":[81,160,164],"new":[82,88,145,165],"disease":[83,136],"recurrence":[84],"The":[86,152],"five":[87],"all":[92],"comorbidity-related":[93],"deaths":[94],"without":[95],"CSCC":[96],"recurrence.":[97,137],"Overall":[98,138],"54-month":[100,140],"76.2%":[103],"(81.5%":[104],"patients":[106,111,118,130],"pCR,":[108,132],"88.9%":[109],"major":[113],"response,":[115,122],"100%":[116],"partial":[120],"45.7%":[124],"nonresponders/not-evaluable":[126],"patients).":[127],"Among":[128],"40":[129],"none":[133],"had":[134],"experienced":[135],"OS":[141],"79.4%.":[143],"No":[144],"grade":[146],"\u22653":[147],"treatment-emergent":[148],"adverse":[149],"occurred.":[151],"analysis":[154],"demonstrates":[155],"durable":[156],"OS,":[159],"late":[161],"recurrences,":[162],"safety":[166],"signals":[167],"cemiplimab.":[170]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2026-10-25T00:00:00"}